Full Year 2025 Revenio Group Oyj Earnings Call Transcript
Key Points
- Revenio Group Oyj (STU:R0V) reported a currency-adjusted net sales growth of 9.1% for the full year 2025, totaling 109.7 million euros.
- The company achieved an all-time sales record in the USA during December 2025, indicating strong market performance.
- Strong cash flow was reported, ending at approximately 30 million euros, up from 23 million euros the previous year.
- Revenio Group Oyj successfully launched new products in 2025, including the Maya microperimeter and a data management solution FDA cleared in the USA.
- The company has been focusing on strategic growth areas such as tonometry, fundus imaging, and microperimetry, which are expected to drive future sales growth.
- Profitability was impacted by delayed price increases and non-recurring costs, affecting the EBIT performance for Q4 2025.
- The company faced increased costs related to FDA trials, which are expected to continue into 2026, potentially impacting profitability.
- APAC region sales were down year-on-year, although there was some improvement in Q4 compared to Q3.
- The gross margin was affected by tariffs, and price increases were not fully implemented in the US during the last quarter.
- Revenio Group Oyj's earnings per share slightly decreased compared to the previous year, indicating pressure on profitability.
Good afternoon, from snowy Finland, and welcome to Revenue and full year 2025 earnings call.
My name is Jouni Toijala. I'm the group, CEO for Revenue, and then with me, as always, we have a Robin Bulkkin and, here as a CFO.
Plan for today is to go through, the business, highlights, for Q4 2025, and then couple of highlights also, from the, whole 2025.
And then we are going to go through recap regarding to the three year strategy period, focusing on the strategy execution during 25 and then Robin is going to take over and go through the finances for the Q4 2025 and then the whole year 2025 and then we'll finish up with the guidance for 26 and of course, the Q&A at the end.
Q4, net sales, grew, to the 31.2 million, so reported growth, 2.2%. Currency adjusted, growth, 8.6%. And if you think, and go back, for the Q4 from the region perspective, so Q4.
US sales, grew strongly and we received the all-time sales record in the USA, during the December. Also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
